A Phase 3, Multicenter, Randomized, Open-label, Active-controlled Study of DS-8201a, an Anti-HER2-antibody Drug Conjugate, Versus Treatment of Investigator's Choice for HER2-positive, Unresectable and/or Metastatic Breast Cancer Subjects Pretreated With Prior Standard of Care HER2 Therapies, Including T-DM1
What is the purpose of this trial?
This study will compare DS 8201a to standard treatment.
Participants must have HER2 breast cancer that has been treated before.
- cannot be removed by an operation
- has spread to other parts of the body
- Trial withDaiichi Sankyo
- Start Date07/01/2019
- End Date01/31/2022
- Last Updated08/22/2019
- Study HIC#2000024234